|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
82,270,000 |
Market
Cap: |
443.44(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$2.34 - $13.01 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Revance Therapeutics is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. Co.'s segments are: Product, which refers to the business that includes the research, development and commercialization of its product candidates and the RHA® Collection of dermal fillers; and Service, which refers to the business that includes the development and commercialization of the OPUL Relational Commerce Platform and HintMD platform.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
Total Buy Value |
$0 |
$0 |
$209,400 |
$209,400 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
2,392 |
29,089 |
435,160 |
Total Sell Value |
$0 |
$9,096 |
$143,717 |
$12,421,724 |
Total People Sold |
0 |
1 |
4 |
5 |
Total Sell Transactions |
0 |
1 |
4 |
26 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Joshi Abhay |
COO, President, R&D |
|
2020-02-15 |
4 |
D |
$25.33 |
$84,222 |
D/D |
(3,325) |
103,186 |
|
- |
|
Mcdowell Caryn Gordon |
SVP, GC & Secretary |
|
2020-02-15 |
4 |
D |
$25.33 |
$21,885 |
D/D |
(864) |
23,453 |
|
- |
|
Sjuts Dustin S |
Chief Commercial Officer |
|
2020-02-15 |
4 |
D |
$25.33 |
$7,295 |
D/D |
(288) |
33,496 |
|
- |
|
Schilke Tobin |
CFO |
|
2020-02-15 |
4 |
D |
$25.33 |
$14,590 |
D/D |
(576) |
38,795 |
|
- |
|
Joshi Abhay |
Chief Operating Officer |
|
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
106,511 |
|
- |
|
Schilke Tobin |
CFO |
|
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
16,500 |
39,371 |
|
- |
|
Foley Mark J |
CEO & President |
|
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
413,500 |
|
- |
|
Sjuts Dustin S |
Chief Commercial Officer |
|
2020-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
33,784 |
|
- |
|
Joshi Abhay |
Chief Operating Officer |
|
2020-01-15 |
4 |
D |
$22.89 |
$101,654 |
D/D |
(4,441) |
81,511 |
|
- |
|
Sjuts Dustin S |
Chief Commercial Officer |
|
2019-12-31 |
4 |
A |
$10.82 |
$4,133 |
D/D |
382 |
13,784 |
|
- |
|
Mcdowell Caryn Gordon |
SVP, GC & Secretary |
|
2019-12-31 |
4 |
A |
$10.82 |
$4,133 |
D/D |
382 |
24,317 |
|
- |
|
Schilke Tobin |
CFO |
|
2019-12-31 |
4 |
A |
$10.82 |
$5,453 |
D/D |
504 |
22,871 |
|
- |
|
Sjuts Dustin S |
Chief Commercial Officer |
|
2019-12-15 |
4 |
D |
$15.99 |
$9,210 |
D/D |
(576) |
11,492 |
|
- |
|
Schilke Tobin |
CFO |
|
2019-12-15 |
4 |
D |
$15.99 |
$24,880 |
D/D |
(1,556) |
22,367 |
|
- |
|
Joshi Abhay |
Chief Operating Officer |
|
2019-12-14 |
4 |
D |
$15.99 |
$47,506 |
D/D |
(2,971) |
85,952 |
|
- |
|
Sjuts Dustin S |
Chief Commercial OfficerOffice |
|
2019-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,068 |
|
- |
|
Foley Mark J |
CEO & President |
|
2019-10-13 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
213,500 |
|
- |
|
Nolet Chris |
Director |
|
2019-07-16 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
Browne L Daniel |
CEO and President |
|
2019-06-28 |
4 |
A |
$11.02 |
$11,025 |
D/D |
1,000 |
152,193 |
|
- |
|
Mcdowell Caryn Gordon |
SVP, GC & Secretary |
|
2019-06-28 |
4 |
A |
$11.02 |
$11,025 |
D/D |
1,000 |
23,935 |
|
- |
|
Schilke Tobin |
CFO |
|
2019-06-28 |
4 |
A |
$11.02 |
$10,176 |
D/D |
923 |
23,923 |
|
- |
|
Mcdowell Caryn Gordon |
SVP, GC & Secretary |
|
2019-06-15 |
4 |
D |
$10.86 |
$15,019 |
D/D |
(1,383) |
22,935 |
|
- |
|
Beraud Jill |
Director |
|
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
Russell Angus C. |
Director |
|
2019-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
10,500 |
|
- |
|
Vickers Philip J. |
Director |
|
2019-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
13,650 |
|
- |
|
404 Records found
|
|
Page 8 of 17 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|